[Alpha-1-blockers (alfuzosin) for obstructive salivary gland diseases].
BACKGROUND
Alpha-blockers are used in urology to treat stenosis and lithiasis. The pathophysiology is similar in salivary glands. We had for aim to assess the safety and effectiveness of an alpha-blocker (Alfuzosin) in patients with ductal stenosis, allergic pseudo-parotitis or sialolithiasis after lithotripsy.


METHODS
Three hundred and fifty-two patients were included, 194 of whom presented with sialolithiasis fragmented by extracorporeal lithotripsy (112 parotidic and 82 submandibular). Sixty-nine presented with ductal stenosis, and 89 with allergic pseudo-parotitis. This retrospective study lasted 3 years (January 2005 to January 2008) with a mean follow-up of 33 months (18 months to 4 years). Male patients were given 2.5mg tid of the alpha-blocker Alfuzosin and female patients 2.5mg bid for 3 to 24 months. After 6 months and up to 2 years of treatment, patients were assessed every 3 months by US and with a questionnaire on symptoms.


RESULTS
Results were similar in male and female patients. Eighty percent of patients with colic-like pain due to stenosis reported a significant improvement after treatment. 78.6% of patients with allergic pseudo-parotitis felt they had improved and noted a sharp decrease of pruritus. Sixty-seven of the patients with residual parotid lithiasis after extracorporeal lithotripsy presented with less ductal lithiasis and fragments were evacuated more rapidly in the two months following lithotripsy. Forty-two percent of the patients treated for residual submandibular lithiasis reported a significant functional improvement and faster evacuation of fragments. Twelve patients out of 352 (3.4%) reported adverse effects. The incidence of orthostatic hypotension was 2.2%.


CONCLUSIONS
A significant improvement of symptoms was observed in patients treated with Alfuzosin for obstructive salivary gland diseases. The drug was well tolerated. These preliminary results are good in terms of effectiveness and inocuity. They should be confirmed with a prospective controlled study.
Guerre
A
A
Institut d'explorations fonctionnelles et d'endoscopie des glandes salivaires, 7, rue Théodore-de-Banville, 75017 Paris, France. agnes.guerre@gmail.com
Hartl
D-M
DM
Katz
P
P
D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D003085:Colic / Q000188:drug therapy; D003251:Constriction, Pathologic / Q000188:drug therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy; D007024:Hypotension, Orthostatic / Q000139:chemically induced; D008096:Lithotripsy; D008297:Male; D008875:Middle Aged; D010305:Parotid Diseases / Q000188:drug therapy / Q000628:therapy; D010309:Parotitis / Q000188:drug therapy; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D018987:Salivary Ducts / Q000187:drug effects; D015494:Salivary Gland Calculi / Q000188:drug therapy / Q000628:therapy; D012466:Salivary Gland Diseases / Q000188:drug therapy*; D013364:Submandibular Gland Diseases / Q000188:drug therapy / Q000628:therapy; D016896:Treatment Outcome
D000317:Adrenergic alpha-Antagonists; D011799:Quinazolines; C047638:alfuzosin